#United States #San Diego #Johnson Fistel #Soleno Therapeutics #VYKAT

Johnson Fistel Conducts Investigation for Soleno Therapeutics Shareholders

In a significant move for investors, Johnson Fistel, PLLP, a law firm specializing in shareholder rights, has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO). This inquiry focuses on whether Soleno or its key officers and directors violated federal securities laws by making statements that misled investors or failing to disclose pertinent information.

Background of the Investigation

The investigation arises from the circumstances surrounding Soleno’s product, VYKAT™ XR, which gained approval from the FDA in September 2025. After this release, Soleno had assured its investors that the product's rollout was exceeding expectations. However, subsequent communications revealed a different story. During a conference call on November 4, 2025, company management discussed unexpected hurdles, including a noticeable decline in new treatment initiations and an increase in therapy discontinuations due to non-serious adverse events.

The timing of these revelations raised concerns about Soleno's credibility. For instance, a report released by the short-selling firm Scorpion Capital on August 15, 2025, raised serious concerns about the drug's safety profile and the company's commercialization strategy. The report suggested that Soleno's business model heavily relies on VYKAT™ XR and also pointed out issues regarding the sustainability of demand.

The Impact on Shareholders

The fallout from Scorpion Capital's report was immediate, resulting in significant volatility in Soleno's stock price. Between August 14 and November 5, 2025, shares of Soleno experienced a drastic plunge of nearly 40%. These developments have prompted Johnson Fistel to invite SLNO shareholders who have incurred losses to join their investigation. This movement seeks to examine whether they can hold the company accountable for any potential wrongdoing during this turbulent period.

A Closer Look at the Allegations

The law firm aims to ascertain whether Soleno's communications were indeed reflective of its operational challenges and the drug's safety profile as per their public announcements. If it is found that the information published by the company was misleading or false, affected investors may be entitled to file a securities fraud lawsuit. This could result in substantial compensation for those who suffered financial loss.

As the investigation progresses, numerous questions remain. Did Soleno and its executives genuinely believe the optimistic statements they made about the product's launch? Or were they aware of the challenges yet continued to mislead investors for gain?

What Investors Should Do

Investors who purchased Soleno stocks and experienced losses are encouraged to participate in the ongoing investigation orchestrated by Johnson Fistel. Their initiative is structured to ensure that shareholders are aware of their rights and can pursue any legal action that may be warranted.

If you are an investor affected by Soleno’s actions, you can find more information and express your interest in joining the investigation by visiting the Johnson Fistel website.

About Johnson Fistel, PLLP

Founded with a commitment to protecting shareholders' rights, Johnson Fistel has garnered a reputation as a leading law firm in securities litigation. The firm has successfully recovered substantial sums for investors in various securities class action lawsuits and also represents international investors through U.S. exchanges. The 2024 ranking among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services further bolsters its reputation.

For further inquiries or to participate in the investigation, affected investors can contact Jim Baker directly at [email protected] or call (619) 814-4471, with no charges or obligations.

Conclusion

The ongoing investigation into Soleno Therapeutics serves as a critical reminder for investors to remain vigilant about the accuracy of information provided by companies in which they invest. With shareholder rights attorneys at the helm, those impacted by the company's recent downturn will have the opportunity to seek justice and possibly recover some of their losses in this evolving situation.